Oculis Raises CHF15.5 Million in an Extension of its Series B Financing Round - Total Raised CHF35.5 Million
New funds to expand portfolio and advance development of novel topical treatments for ophthalmic diseases
LAUSANNE, Switzerland, January 4, 2019 -- (Healthcare Sales & Marketing Network) -- Oculis SA, a clinical-stage biopharmaceutical company developi... Biopharmaceuticals, Ophthalmology, Venture Capital Oculis , Diabetic Macular Edema
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Diabetes | Endocrinology | Marketing | Opthalmology | Pharmaceuticals | Switzerland Health | Venture Capital